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Abstract
Concerns exist about the serologic response to yellow fever (YF) vaccine when given within 28 
days of another live virus vaccine. We report the case of a healthy adult who received 17D YF 
vaccine 21 days following administration of another live viral vaccine, and developed a protective 
level of immunity against YF virus.
In its general recommendations on immunization, the Advisory Committee on Immunization 
Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) cautions that 
“the immune response to one live-virus vaccine might be impaired if administered within 28 
days … of another live-virus vaccine.”1 Therefore to minimize the potential risk for 
interference, it is recommended that injectable or nasally administered live vaccines should 
be given on the same day or ≥4 weeks apart. If the live vaccines are administered non-
simultaneously and within 4 weeks, it is recommended that the second vaccine administered 
should be repeated. We report the successful vaccination and generation of a protective 
immune response to yellow fever (YF) vaccine that was administered to an adult traveler 21 
days after receiving another live viral vaccine.
Case Report
A 60-year-old female was seen at the Adult Immunization and Travel Clinic of the San 
Francisco Department of Public Health 6 days prior to departing on a 2-week visit to 
western Uganda. She was born and resided in the United States, was in good health, and had 
no history of prior flavivirus infection, receipt of YF or Japanese encephalitis vaccinations, 
or travel to a YF endemic area. The CDC recommends that all travelers ≥9 months of age 
visiting Uganda be vaccinated against YF.2 Furthermore, at the time of consultation there 
was even greater concern about the risk of natural infection because of an outbreak of YF 
occurring in the northern part of the country.3 The client reported receiving an injection of 
zoster vaccine (Zostavax, Merck Sharp&Dohme, Whitehouse Station, NJ, USA), a live-
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attenuated viral vaccine, at a pharmacy 21 days earlier. We informed her that the live zoster 
vaccine could affect her response to YF vaccine, and that she could be at increased risk of an 
adverse reaction to YF vaccine due to her age.4 Despite these considerations, and in light of 
the ongoing outbreak, she agreed with our recommendation in favor of vaccination against 
YF. We administered YF vaccine (YF-Vax; Sanofi Pasteur, Swiftwater, PA, USA) as well 
as inactivated vaccines against typhoid, meningococcal infection, and polio (Typhim Vi, 
Menactra, and IPOL; Sanofi Pasteur). We also prescribed a regimen of daily malaria 
chemoprophylaxis with atovaquone–proguanil, and instructed her to use prevention 
measures to reduce her mosquito exposure.
She returned to our clinic 5 weeks later, in preparation for a 6-month trip to the same region 
in Uganda. According to published CDC recommendations, she should have been given a 
second dose of YF vaccine. However, because her age was a precaution to initial 
vaccination, and since there was sufficient time to do so, we opted to check her immunity to 
YF before administering a second dose of the vaccine. A serum specimen was obtained and 
analyzed at the CDC Division of Vector-Borne Diseases in Fort Collins, Colorado, for 
neutralizing antibodies against YF virus. At CDC, a 90% endpoint plaque reduction 
neutralization test (PRNT90) titer of ≥20 is considered protective against YF virus 
infection.4 Our client had a titer of 1,280 in her serum obtained 35 days after vaccination.
Discussion
Infection with YF virus, a mosquito-borne flavivirus, most commonly is asymptomatic or 
causes mild febrile illness. However, it can cause severe disease with jaundice, hemorrhagic 
diathesis, and multiorgan failure. The case-fatality rate for severe YF with hepatorenal 
failure is 20% to 50%. YF-Vax contains the 17D substrain of YF virus and is highly 
immunogenic; at 28 days following a single dose, over 99% of healthy persons develop 
neutralizing antibodies to YF virus.4
Relatively little is known about the serologic response to YF vaccine when administered 
within 4 weeks of another live vaccine, and the few published studies examining such 
interactions report disparate findings. One study showed that 9-month-olds immunized with 
YF vaccine showed similar rates of YF seroconversion, regardless of the timing of recent 
vaccination with live-attenuated measles vaccine (>27 d before YF vaccine vs ≤27 d 
before).5 A more recent study with 12- to 23-month-olds has suggested that lower rates of 
conversion to YF seropositivity are induced by administering YF vaccine and a combined 
live virus vaccine against measles, mumps, and rubella concomitantly, compared with 
administration 30 days apart.6 No data have been published regarding possible interference 
between YF vaccine and several other live vaccines, including varicella-zoster virus-
containing vaccines.
Although this is a single case report which might not be generalizable to a larger population, 
our findings indicate that it is possible for a healthy adult to generate a robust antibody 
response to a dose of YF virus vaccine administered only 3 weeks after immunization with 
live zoster vaccine. Additional studies are warranted to more thoroughly examine the 
immune response to YF vaccine when administered non-simultaneously and within 4 weeks 
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of another live vaccine; however, it is unlikely that randomized trials would be undertaken 
due to both the theoretical risk of impairing immunity in recipients and the risks associated 
with vaccination. Thus for persons who receive YF vaccine within 28 days of another live 
vaccine, either inadvertently or because the benefits are deemed to outweigh the potential 
risks of impaired immune response, practitioners are encouraged to test for an appropriate 
neutralizing antibody response and report their findings. These data will help to improve our 
understanding of potential interference, if any, that might occur between YF vaccine and 
other live vaccines administered non-simultaneously.
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